Investigational Drug Information for Poziotinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Poziotinib?
Poziotinib is an investigational drug.
There have been 21 clinical trials for Poziotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 12th 2022.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.
There are fifty US patents protecting this investigational drug and five hundred and seventy-six international patents.
Summary for Poziotinib
US Patents | 50 |
International Patents | 576 |
US Patent Applications | 233 |
WIPO Patent Applications | 253 |
Japanese Patent Applications | 32 |
Clinical Trial Progress | Phase 2 (2022-05-12) |
Vendors | 66 |
Recent Clinical Trials for Poziotinib
Title | Sponsor | Phase |
---|---|---|
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations | Spectrum Pharmaceuticals, Inc | Phase 3 |
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer | M.D. Anderson Cancer Center | Phase 2 |
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants | Spectrum Pharmaceuticals, Inc | Phase 1 |
Clinical Trial Summary for Poziotinib
Top disease conditions for Poziotinib
Top clinical trial sponsors for Poziotinib
US Patents for Poziotinib
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Poziotinib | See Plans and Pricing | Compounds and methods for inhibiting vacuolar ATPase | University of Southern California (Los Angeles, CA) | See Plans and Pricing |
Poziotinib | See Plans and Pricing | Gene fusions and gene variants associated with cancer | LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) | See Plans and Pricing |
Poziotinib | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
Poziotinib | See Plans and Pricing | Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 | Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) | See Plans and Pricing |
Poziotinib | See Plans and Pricing | In vitro model for a tumor microenvironment | HemoShear, LLC (Charlottesville, VA) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Poziotinib
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Poziotinib | Australia | AU2014254394 | 2033-04-17 | See Plans and Pricing |
Poziotinib | China | CN105378110 | 2033-04-17 | See Plans and Pricing |
Poziotinib | China | CN106414768 | 2033-04-17 | See Plans and Pricing |
Poziotinib | European Patent Office | EP2986736 | 2033-04-17 | See Plans and Pricing |
Poziotinib | European Patent Office | EP3122901 | 2033-04-17 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |